Brian D Adkins

Dr. Brian D Adkins

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
JJJeremy W. Jacobs
Jeremy W. Jacobs
CVCristina A. Figueroa Villalba
Cristina A. Figueroa Villalba
GBGarrett S. Booth
Garrett S. Booth
JWJennifer S. Woo
Jennifer S. Woo
LSLaura D. Stephens
Laura D. Stephens
BABrian D Adkins
Brian D Adkins
Paroxysmal cold hemoglobinuria (PCH) is a rare autoimmune hemolytic anemia often overlooked as a potential etiology of hemolysis and is challenging to diagnose because of the complicated testing methods required. We performed a systematic review of all reported cases to better assess the clinical, immunohematologic, and therapeutic characteristics of PCH. We systematically analyzed PubMed, Medline, and EMBASE to identify all cases of PCH confirmed by Donath-Landsteiner (DL) testing. Three authors independently screened articles for inclusion, and systematically extracted epidemiologic, clinical, laboratory, treatment, and outcomes data. Discrepancies were adjudicated by a fourth author. We identified 230 cases, with median presentation hemoglobin of 6.5 g/dL and nadir of 5.5 g/dL. The most common direct antiglobulin test (DAT) result was the presence of complement and absence of immunoglobulin G (IgG) bound to red blood cells, although other findings were observed in one-third of cases. DL antibody class and specificity were reported for 71 patients, of which 83.1% were IgG anti-P. The use of corticosteroids is common, although we found no significant difference in the length of hospitalization for patients with and without steroid therapy. Recent reports have highlighted the use of complement inhibitors. Among patients with follow-up, 99% (213 of 216) were alive at the time of reporting. To our knowledge, this represents the largest compilation of PCH cases to date. We discovered that contemporary PCH most commonly occurs in children with a preceding viral infection, corticosteroid use is frequent (but potentially ineffective), and DAT results are more disparate than traditionally reported.

28 February 2018 in Cytopathology
Verified
Journal Article
Closed access
PDF file
BABrian D Adkins
Brian D Adkins
ABA. B. Barlow
A. B. Barlow
AJA. Jack
A. Jack
SSS. J. Schultenover
S. J. Schultenover
MDM. M. Desouki
M. M. Desouki
VWVivian Weiss
Vivian Weiss

25 April 2023 in American Journal of Hematology
Verified
Journal Article
Closed access
JJJeremy W. Jacobs
Jeremy W. Jacobs
MDMarlon Diaz
Marlon Diaz
DSDory E. Arevalo Salazar
Dory E. Arevalo Salazar
ATAlbert Tang
Albert Tang
LSLaura D. Stephens
Laura D. Stephens
BABrian D Adkins
Brian D Adkins

20 June 2019 in Head and Neck Pathology
Verified
Journal Article
Closed access
PDF file
BABrian D Adkins
Brian D Adkins
AGAriana Geromes
Ariana Geromes
LZLily Y. Zhang
Lily Y. Zhang
RCRebecca Chernock
Rebecca Chernock
KKKatherine Kimmelshue
Katherine Kimmelshue
KEKim Ely
Kim Ely

25 March 2024 in Clinical Hematology International
Verified
Journal Article
Open access
PDF file
BABrian D Adkins
Brian D Adkins
JJJeremy W. Jacobs
Jeremy W. Jacobs
GBGarrett S. Booth
Garrett S. Booth
BSBipin N. Savani
Bipin N. Savani
LSLaura D. Stephens
Laura D. Stephens
Hematopoietic stem cell transplantation (HSCT) is a cornerstone of modern medical practice, and can only be performed safely and effectively with appropriate transfusion medicine support. Patients undergoing HSCT often develop therapy-related cytopenia, necessitating differing blood product requirements in the pre-, peri-, and post-transplant periods. Moreover, ensuring optimal management for patients alloimmunized to human leukocyte antigens (HLA) and/or red blood cell (RBC) antigens, as well as for patients receiving ABO-incompatible transplants, requires close collaboration with transfusion medicine and blood bank professionals. Finally, as updated transfusion guidelines and novel blood product modifications emerge, the options available to the transplant practitioner continue to expand. Herein, we detail contemporary blood transfusion and transfusion medicine practices for patients undergoing HSCT.